The integrative FD-reprogramming lactate metabolite signatures and mTOR/AMPK/HIF-1α-signaling-mediated druggable targets in the FD/LCS-promoted LC metastatic tumor microenvironment are illustrated in Figure 7. The gene discussed is HIF1A; the disease is laryngotracheoesophageal cleft.